Table 1 Clinicopathological characteristics of patients with T1-T3N0M0 RPTCC
Total (N = 1375) | Training cohort (N = 977) | Validation cohort (N = 398) | p | |
|---|---|---|---|---|
Age | 0.355 | |||
65–69 | 267 (19.4%) | 182 (18.6%) | 85 (21.4%) | |
70–74 | 297 (21.6%) | 205 (21.0%) | 92 (23.1%) | |
75–79 | 308 (22.4%) | 231 (23.6%) | 77 (19.3%) | |
80–84 | 290 (21.1%) | 210 (21.5%) | 80 (20.1%) | |
> 84 | 213 (15.5%) | 149 (15.3%) | 64 (16.1%) | |
Race | 0.048 | |||
White | 1204 (87.6%) | 862 (88.2%) | 342 (85.9%) | |
Black | 55 (4.00%) | 43 (4.40%) | 12 (3.02%) | |
Othera | 116 (8.44%) | 72 (7.37%) | 44 (11.1%) | |
Sex | 0.996 | |||
Male | 772 (56.1%) | 548 (56.1%) | 224 (56.3%) | |
Female | 603 (43.9%) | 429 (43.9%) | 174 (43.7%) | |
Year of diagnosis | 0.540 | |||
2004–2008 | 381 (27.7%) | 275 (28.1%) | 106 (26.6%) | |
2009–2013 | 484 (35.2%) | 335 (34.3%) | 149 (37.4%) | |
2014–2018 | 510 (37.1%) | 367 (37.6%) | 143 (35.9%) | |
Laterality | 0.864 | |||
Left | 705 (51.3%) | 499 (51.1%) | 206 (51.8%) | |
Right | 670 (48.7%) | 478 (48.9%) | 192 (48.2%) | |
AJCC stage | 0.710 | |||
I | 515 (37.5%) | 372 (38.1%) | 143 (35.9%) | |
II | 199 (14.5%) | 142 (14.5%) | 57 (14.3%) | |
III | 661 (48.1%) | 463 (47.4%) | 198 (49.7%) | |
Marriage | 0.414 | |||
No | 576 (41.9%) | 402 (41.1%) | 174 (43.7%) | |
Yes | 799 (58.1%) | 575 (58.9%) | 224 (56.3%) | |
Grade | 0.580 | |||
I/II | 218 (15.9%) | 151 (15.5%) | 67 (16.8%) | |
III/IV | 1157 (84.1%) | 826 (84.5%) | 331 (83.2%) | |
Surgery | 0.844 | |||
No Surgery | 23 (1.67%) | 17 (1.74%) | 6 (1.51%) | |
Local tumor excision | 29 (2.11%) | 19 (1.94%) | 10 (2.51%) | |
Partial nephrectomy | 30 (2.18%) | 20 (2.05%) | 10 (2.51%) | |
Radical nephrectomy | 1293 (94.0%) | 921 (94.3%) | 372 (93.5%) | |
Radiotherapy | 0.610 | |||
No | 1356 (98.6%) | 965 (98.8%) | 391 (98.2%) | |
Yes | 19 (1.38%) | 12 (1.23%) | 7 (1.76%) | |
Chemotherapy | 0.276 | |||
No | 1191 (86.6%) | 853 (87.3%) | 338 (84.9%) | |
Yes | 184 (13.4%) | 124 (12.7%) | 60 (15.1%) | |
Tumor size | 0.233 | |||
< 2 cm | 225 (16.4%) | 150 (15.4%) | 75 (18.8%) | |
2–4 cm | 672 (48.9%) | 488 (49.9%) | 184 (46.2%) | |
> 4 cm | 478 (34.8%) | 339 (34.7%) | 139 (34.9%) | |
Survival months (mean (SD)) | 47.3 (39.4) | 47.1 (39.6) | 47.6 (39.0) | 0.851 |
Survival months (median (IQR)) | 37 (16, 69) | 36(16, 69) | 38.5 (16, 69) | 0.705 |
Status | 0.480 | |||
Alive | 622 (45.2%) | 452 (46.3%) | 170 (42.7%) | |
Cancer cause of death | 426 (31.0%) | 296 (30.3%) | 130 (32.7%) | |
Other cause of death | 327 (23.8%) | 229 (23.4%) | 98 (24.6%) |